JP6283688B2 - カゼインキナーゼ１ｄ／ｅ阻害剤としての新規なピラゾール置換のイミダゾピラジン - Google Patents

カゼインキナーゼ１ｄ／ｅ阻害剤としての新規なピラゾール置換のイミダゾピラジン Download PDF

Info

Publication number
JP6283688B2
JP6283688B2 JP2015549758A JP2015549758A JP6283688B2 JP 6283688 B2 JP6283688 B2 JP 6283688B2 JP 2015549758 A JP2015549758 A JP 2015549758A JP 2015549758 A JP2015549758 A JP 2015549758A JP 6283688 B2 JP6283688 B2 JP 6283688B2
Authority
JP
Japan
Prior art keywords
substituted
alkyl
heterocyclyl
carbocyclyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015549758A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016508135A5 (enExample
JP2016508135A (ja
Inventor
アッペンダー・ベラパルチ
チェタン・パドマカル・ダルネ
ダームパル・エス・ドッド
ペイイン・リウ
クリストファー・ピー・マッサリ
マーク・ディ・ウィットマン
セルヴァクマル・クマラヴェル
ディバカル・ムリック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2016508135A publication Critical patent/JP2016508135A/ja
Publication of JP2016508135A5 publication Critical patent/JP2016508135A5/ja
Application granted granted Critical
Publication of JP6283688B2 publication Critical patent/JP6283688B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2015549758A 2012-12-21 2013-12-20 カゼインキナーゼ１ｄ／ｅ阻害剤としての新規なピラゾール置換のイミダゾピラジン Expired - Fee Related JP6283688B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261740552P 2012-12-21 2012-12-21
US61/740,552 2012-12-21
PCT/US2013/076806 WO2014100540A1 (en) 2012-12-21 2013-12-20 Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors

Publications (3)

Publication Number Publication Date
JP2016508135A JP2016508135A (ja) 2016-03-17
JP2016508135A5 JP2016508135A5 (enExample) 2017-01-12
JP6283688B2 true JP6283688B2 (ja) 2018-02-21

Family

ID=49943574

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015549758A Expired - Fee Related JP6283688B2 (ja) 2012-12-21 2013-12-20 カゼインキナーゼ１ｄ／ｅ阻害剤としての新規なピラゾール置換のイミダゾピラジン

Country Status (5)

Country Link
US (1) US9475817B2 (enExample)
EP (1) EP2935272B1 (enExample)
JP (1) JP6283688B2 (enExample)
CN (1) CN104837844B (enExample)
WO (1) WO2014100540A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2935271B1 (en) 2012-12-21 2017-10-25 Bristol-Myers Squibb Company Novel substituted imidazoles as casein kinase 1 / inhibitors
EP3157925B1 (en) 2014-06-19 2019-12-18 Bristol-Myers Squibb Company Imidazo-pyridazine derivatives as casein kinase 1 delta/epsilon inhibitors
EP4591936A3 (en) 2015-03-23 2025-10-15 Tianli Biotech Pty Ltd Treatment of respiratory diseases
CN105418615B (zh) * 2015-12-09 2018-02-02 北京工业大学 苯甲酰胺衍生物及制备和应用
WO2018017633A1 (en) 2016-07-21 2018-01-25 Bristol-Myers Squibb Company TGF Beta RECEPTOR ANTAGONISTS
WO2020093098A1 (en) 2018-11-07 2020-05-14 The University Of Melbourne Novel compounds for the treatment of respiratory diseases
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CA3139285A1 (en) * 2019-06-27 2020-12-30 Hangzhou Healzen Therapeutics Co., Ltd. Casein kinase 1e inhibitor, pharmaceutical composition and application thereof
CN112451529A (zh) * 2020-12-18 2021-03-09 忻佑康医药科技(南京)有限公司 Kb-NB 142-70的药物新用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
JPWO2008016131A1 (ja) 2006-08-04 2009-12-24 武田薬品工業株式会社 縮合複素環化合物
FR2918986B1 (fr) * 2007-07-19 2009-09-04 Sanofi Aventis Sa Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique
CA2710194C (en) 2007-12-19 2014-04-22 Amgen Inc. Inhibitors of p13 kinase
CN101981033B (zh) * 2008-02-06 2015-02-04 百时美施贵宝公司 用作激酶抑制剂的取代的咪唑并哒嗪化合物
FR2940284B1 (fr) * 2008-12-19 2011-02-18 Sanofi Aventis Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique
FR2940285A1 (fr) * 2008-12-19 2010-06-25 Sanofi Aventis Derives de 6-cycloamino-2-thienyl-3-(pyridin-4-yl)imidazo °1,2-b!-pyridazine et 6-cycloamino-2-furanyl-3- (pyridin-4-yl)imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
PL3181133T3 (pl) * 2010-12-20 2019-12-31 Pfizer Inc. Nowe skondensowane związki pirydyny jako inhibitory kinazy kazeiny
EP2935271B1 (en) 2012-12-21 2017-10-25 Bristol-Myers Squibb Company Novel substituted imidazoles as casein kinase 1 / inhibitors

Also Published As

Publication number Publication date
CN104837844A (zh) 2015-08-12
EP2935272A1 (en) 2015-10-28
US20150344480A1 (en) 2015-12-03
CN104837844B (zh) 2017-08-29
WO2014100540A1 (en) 2014-06-26
US9475817B2 (en) 2016-10-25
EP2935272B1 (en) 2017-02-22
JP2016508135A (ja) 2016-03-17

Similar Documents

Publication Publication Date Title
JP6283688B2 (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての新規なピラゾール置換のイミダゾピラジン
JP6267231B2 (ja) カゼインキナーゼ１δ／ε阻害剤としての新規な置換イミダゾール
US9598423B2 (en) Substituted 4,5,6,7-tetrahydropyrazolo[1,5-A]pyrazine derivatives as casein kinase 1 D/E inhibitors
JP6564406B2 (ja) カゼインキナーゼ１デルタ／イプシロン阻害剤としてのイミダゾ−ピリダジン誘導体
JP6373978B2 (ja) イミダゾピロリジノン誘導体および疾患の処置におけるその使用
JP5560278B2 (ja) キナーゼ阻害剤として有用なイミダゾピリダジンカルボニトリル
US9550796B2 (en) Pyrrolopyrrolone derivatives and their use as BET inhibitors
EP2552922A1 (en) Substituted pyrrolotriazines as protein kinase inhibitors
MX2013006054A (es) Compuestos de triazolopiridina.
JP2010505922A (ja) 新規なイミダゾロン誘導体、医薬としてのそれの製造、医薬組成物、およびタンパク質キナーゼ阻害薬、特にｃｄｃ７阻害薬としてのそれの使用
JP7537002B2 (ja) Ｃｄｋ９阻害剤およびその使用

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161118

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180111

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180123

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180129

R150 Certificate of patent or registration of utility model

Ref document number: 6283688

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees